Eyegate Pharmaceuticals Inc. is looking to raise $10 million via a public offering.

The company will issue 6,666,667 shares at $1.50 apiece, complete with warrants to purchase an additional 6,666,667 stock within five years from the date of issue at the same price.

EyeGate plans to use the net proceeds for clinical trials, working capital and general corporate purposes.

Rodman & Renshaw is acting as the exclusive placement agent for the offering which is expected to close by June 14.